Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
TLR4 agonists have been proposed as immunotherapeutics in cancer. Here, the authors show the TLR4-dependent adjuvant effect of FimH, an E. coli adhesin, in promoting dendritic cell mediated-T cell activation and response to immune checkpoint blockade in preclinical cancer models.
Guardado en:
Autores principales: | Wei Zhang, Li Xu, Hae-Bin Park, Juyoung Hwang, Minseok Kwak, Peter C. W. Lee, Guang Liang, Xiaoyan Zhang, Jianqing Xu, Jun-O Jin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed2a29d550e746acad1fd481acb4d24e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Catch-bond mechanism of the bacterial adhesin FimH
por: Maximilian M. Sauer, et al.
Publicado: (2016) -
FimH-based display of functional eukaryotic proteins on bacteria surfaces
por: Markus Chmielewski, et al.
Publicado: (2019) -
Point mutations in FimH adhesin of Crohn's disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response.
por: Nicolas Dreux, et al.
Publicado: (2013) -
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
por: Sara Nava, et al.
Publicado: (2021) -
Course of the vertical portion of the lower lacrimal canaliculus
por: Hirohiko Kakizaki, et al.
Publicado: (2008)